arsenic trioxide medac
medac gesellschaft für klinische spezialpräparate mbh - trioxid de arsen - leucemie, promielocitară, acută - agenți antineoplazici - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. rata de răspuns de alte leucemie mieloidă acută subtipuri de trioxid de arsen nu a fost examinată.
celestoderm-v unguent 0,1%
schering-plough central east ag - betamethasonum - unguent - 0,1%
celestoderm-v unguent 0,1%
schering-plough central east ag - betamethasonum - unguent - 0,1%
claritine sirop 1 mg/ml
schering-plough central east ag - loratadinum - sirop - 1 mg/ml
afinitor comprimate 2,5 mg
novartis pharma ag - everolimus - comprimate - 2,5 mg
dicloberl supozitoare 50 mg
berlin-chemie ag (menarini group) - diclofenacum - supozitoare - 50 mg
diovan comprimate filmate 160 mg
novartis pharma ag - lisinoprilum - comprimate filmate - 160 mg
diovan comprimate filmate 80 mg
novartis pharma ag - valsartanum - comprimate filmate - 80 mg
elocom crema 1 mg/g
schering-plough central east ag - mometasonum - crema - 1 mg/g
elocom unguent 0,1%
schering-plough central east ag - mometasonum - unguent - 0,1%